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Summary  
A true enigma of modern medicine has persisted for over 150 years. The 
mechanisms by which volatile anesthetics (VAs) produce their effects (loss of 
consciousness, analgesia, amnesia, immobility) remain an unsolved mystery. Many 
attractive putative molecular targets have failed to produce a significant effect when 
genetically tested in whole animal models [1-3]. However, mitochondrial defects 
increase VA sensitivity in diverse organisms from nematodes to humans [4-6]. Ndufs4 
knock-out (KO) mice lack a subunit of mitochondrial complex I and are strikingly 
hypersensitive to VAs, yet resistant to the intravenous anesthetic ketamine [7]. The 
change in VA sensitivity is the largest reported for a mammal. Limiting NDUFS4 loss to 
a subset of glutamatergic neurons recapitulates the VA hypersensitivity of Ndufs4(KO) 
mice, while loss in GABAergic or cholinergic neurons does not. Baseline 
electrophysiologic function of CA1 pyramidal neurons does not differ between 
Ndufs4(KO) and controls. Isoflurane concentrations that anesthetize only Ndufs4(KO) 
mice (0.6%) decreased the frequency of spontaneous excitatory postsynaptic currents 
(sEPSCs) only in Ndufs4(KO) CA1 neurons, while concentrations effective in control 
mice (1.2%) decreased sEPSC frequencies in both control and Ndufs4(KO) CA1 
pyramidal cells. Spontaneous inhibitory postsynaptic frequencies (sIPSCs) were not 
differentially affected between genotypes. The effects of isoflurane were similar on 
evoked field excitatory postsynaptic potentials (fEPSPs) and paired pulse facilitation 
(PPF) in KO and control hippocampal slices. We propose that CA1 pre-synaptic 
excitatory neurotransmission is hypersensitive to isoflurane in Ndufs4(KO) due to 
inhibition of pre-existing reduced complex I function, reaching a critical reduction that 
can no longer meet metabolic demands. 
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Results and Discussion. 
Rationale. To understand the link between mitochondrial complex I dysfunction and 
anesthetic hypersensitivity, we investigated anesthetic behavior of animals which have 
lost NDUFS4 in specific types of neurons. We also compared the synaptic properties of 
hippocampal CA1 pyramidal neurons in young KO animals at baseline and following 
exposure to isoflurane. The CA1 region is a well-characterized region whose response 
to a multitude of anesthetics has been extensively studied, and which also has been 
implicated in the function of VAs [8-12]. Our findings demonstrate specific and 
significant differences between wildtype and KO mice in the effects of isoflurane on 
excitatory pathways. 
 
Complex I dysfunction in VGLUT2-expressing neurons recapitulates 
hypersensitivity to isoflurane and halothane observed in the total KO mice 
We compared the sensitivity to isoflurane and halothane of control mice with that 
of mice with Ndufs4 knocked out selectively in GABAergic neurons (GABA-specific KO 
mice), VGLUT2-positive glutamatergic neurons (VGLUT2-specific KO mice) or 
cholinergic neurons (CHAT-specific KO mice). VGLUT2-specific KO mice were 
markedly hypersensitive to isoflurane and halothane, similar to the total KO mice. 
GABA-specific and CHAT-specific KO mice were not hypersensitive to either halothane 
or isoflurane, except for a small increase in sensitivity of CHAT-specific KO mice to 
halothane (Figure 1). These results support the hypothesis that excitatory glutamatergic 
transmission is the major contributor to volatile anesthetic hypersensitivity of KO mice. 
 
Complex I dysfunction does not affect intrinsic membrane properties and 
synaptic baseline activity in hippocampal CA1 pyramidal neurons 
To understand the link between mitochondrial complex I dysfunction and 
anesthetic hypersensitivity, we investigated intrinsic and synaptic properties of 
hippocampal CA1 pyramidal neurons in KO animals at baseline and following exposure 
to isoflurane. We found no significant differences in the intrinsic membrane properties of 
hippocampal CA1 pyramidal neurons in slices obtained from control and KO mice. The 
resting membrane potential was -61.03 ± 1.24 mV and -62.33 ± 1.05 mV for control and 
KO cells, respectively. Cellular input resistance was 152.39 ± 6.25 MΩ and 148.28 ± 
5.58 MΩ for control and KO cells, respectively. 
No differences were found in sEPSC frequency, amplitude or decay time 
between genotypes (Figure 2A). There were no significant differences between KO and 
control neurons in miniature excitatory post-synaptic current mEPSC frequency, 
amplitude, or decay at baseline (Figure 2B). 
There were no differences in sIPSC frequency, amplitude and decay between 
KO and control neurons (Figure 2C). Finally, there were no differences in miniature 
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inhibitory post-synaptic current (mIPSC) frequency, amplitude and decay between KO 
and control neurons (Figure 2D). 
These results indicate that neuronal function in CA1 hippocampal pyramidal cells 
was not different between control and KO mice in the absence of anesthetic. Thus, 
hypersensitivity to isoflurane in KO mice is not due to a generalized metabolic 
deficiency in basic neuronal function. The specific resistance of the mutant to ketamine 
also supports the conclusion that a general metabolic deficiency is unlikely the 
explanation for the hypersensitivity to volatile anesthetics [7]. 
Our recordings were made before any symptoms or histopathologic changes 
develop in the mutant, and from a region that is relatively spared from degeneration. 
The fact that most parameters studied failed to show differences between control and 
KO cells at baseline is consistent with the fact that ATP concentrations in muscle and 
blood are not decreased in the mutant [13]. In fact, the respiratory capacity of intact 
mitochondria in the KO is 50 - 100 % of the wild-type depending on the complex I 
substrate [14]. Additional sources of ATP such as glycolysis could also compensate to 
some degree in order to maintain network activity at baseline. 
 
CA1 sEPSC frequency is hypersensitive to 0.6% isoflurane in KO neurons. 
We next studied the effects of mitochondrial dysfunction on synaptic activity with 
isoflurane exposure. Exposure to 0.6% isoflurane significantly decreased the sEPSC 
frequency of KO cells without changing the sEPSC frequency of control neurons (Figure 
3A,B). Moreover, sEPSC frequency in KO neurons did not fully revert to pre-exposure 
levels after 15 min of wash with artificial cerebrospinal fluid (ACSF). Interestingly, 
sEPSC amplitudes and decay times were not affected by 0.6% isoflurane exposure in 
either control or KO neurons (Figure 3C,D). In the presence of 1.2% isoflurane sEPSC 
frequency was significantly reduced in both KO and control neurons (Figure 3A,B). As 
was the case for 0.6% isoflurane, sEPSC frequency did not fully recover after 15 min of 
wash in KO cells while sEPSC frequency of control neurons returned to the level prior to 
exposure (Figure 3B). In order to rule-out a possible isoflurane-independent run-down, 
control experiments were performed in which KO cells were voltage-clamped and 
sEPSC frequency was monitored for the duration of the isoflurane treatment 
experiment. No significant change in sEPSC frequency was observed (data not shown). 
Exposure to 1.2% isoflurane did not affect sEPSC amplitude or decay time in either 
control or KO cells (Figure 3C,D). Application of 0.6% isoflurane did not cause any 
changes in mEPSC frequency, amplitude or decay in either genotype (Figure 3E-H). 
Isoflurane caused a specific inhibition of sEPSC frequency only in mutant cells at 
a dose that anesthetized mutant animals but not controls. Control cells showed an 
identical response at a dose that approximated the EC50 of isoflurane in vivo for control 
animals. This implies that the same phenomenon underlies the effect of isoflurane on 
synaptic transmission in both genotypes, and determines the in vivo response. 
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Interestingly, sEPSC frequency in KO cells did not return to baseline following 
exposure to isoflurane. It is unlikely that isoflurane irreversibly binds to its target since 
anesthetized KO mice awaken within 5-10 minutes after removal from 0.4% isoflurane. 
Additionally, membrane potential was maintained throughout cellular recordings 
supporting the conclusion that cell death is not the cause of irreversibility of isoflurane-
induced sEPSC frequency decrease. Since isoflurane is non-detectable in the 
superfusion-recording chamber after 15 minutes of wash as measured by gas 
chromatography, our results could be explained by inability of mitochondria to recover 
ATP levels within the time frame of experiment. Additional studies are required to 
provide mechanistic insights for this phenomenon.  
Studies of the effects of isoflurane on sEPSC parameters on slices from 
GABAergic and cholinergic specific KO mice did not show differences between mutant 
and control slices. Although frequencies decreased in both mutant and control lines, this 
change did not reach significance (Figure S1). Additional effectors may exist for 
synaptic responses to isoflurane. 
 
Isoflurane increases CA1 sIPSC decay time similarly in KO and in control neurons 
sIPSC frequency was not affected by 0.6% isoflurane in either KO or control 
genotypes (Figure S2A,B). Exposure to 0.6% isoflurane slightly decreased sIPSC 
amplitude in control cells without an effect on sIPSC amplitude in KO cells (Figure S2C). 
Application of 0.6% isoflurane increased sIPSC decay time similarly in control and KO 
neurons, which returned to pre-exposure levels after 15 minutes of wash with ACSF 
(Figure S2D). Application of 1.2% isoflurane did not affect sIPSC frequency and 
amplitude of either genotype tested (Figure S2A-C). Exposure to 1.2% isoflurane 
increased sIPSC decay time equally in control and KO neurons (Figure S2D), which 
returned to pre-exposure levels with 15 minutes of wash. 
mIPSC frequency was not affected by 0.6% isoflurane exposure in either control 
or KO cells (Figure S2E,F). mIPSC amplitude decreased slightly, but statistically 
significantly, following exposure to 0.6% isoflurane (Figure S2G). mIPSC amplitude after 
wash was not significantly different from pre-exposure levels. mIPSC decay time 
increased after 0.6% isoflurane exposure in both genotypes similarly and returned to 
pre-exposure level after wash (Figure S2H). 
An anesthetic induced increase in sIPSC decay time is consistent with previous 
reports [15], interpreted to be a result of isoflurane interacting with GABAA receptors 
directly. Mitochondrial complex I dysfunction did not affect sIPSC parameters at 
baseline. sIPSC amplitude demonstrated a small decrease after 0.6% isoflurane 
exposure in control, but not in KO cells. Since mIPSC data did not show any differential 
effect after 0.6% isoflurane exposure, the differential effect of 0.6% isoflurane on sIPSC 
amplitude could be due to differences in GABAergic neuronal spiking. However, the 
magnitude of the effect makes it unlikely to be of biological significance. These results 
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indicate that hippocampal inhibitory circuitry is not affected by mitochondrial complex I 
dysfunction, and that the differential signaling in CA1 neurons between mutant and 
control cells is not the result of increased upstream inhibitory signaling. The lack of 
effect of the loss of NDUFS4 in GABAergic neurons on sensitivity to isoflurane and 
halothane as measured by tail clamp also supports this conclusion. 
 
Isoflurane-induced depression of field excitatory postsynaptic potentials is larger 
in KO slices than in control slices 
We next studied the effects of isoflurane on evoked field excitatory postsynaptic 
potentials (fEPSPs) and paired pulse facilitation (PPF) in KO and control hippocampal 
slices (Figure 4A). At baseline PPF ratios were similar for KO and control slices (Figure 
4B-D). The PPF ratios were not significantly different at various inter-pulse intervals 
ranging from 10-100 ms between control and KO slices (Figure S3). 
Application of 0.6% isoflurane increased the PPF ratio of both control and KO 
slices similarly (Figure 4B,F). In addition, 0.6% isoflurane reversibly decreased the 
amplitudes of first and second fEPSP similarly for control and KO slices (Figure 4B,D). 
Application of 1.2% isoflurane increased the PPF ratio of both control and KO slices 
similarly (Figure 4C,F). In addition, 1.2% isoflurane depressed both first and second 
fEPSPs to a greater extent than 0.6% isoflurane and depressed fEPSPs in KO slices 
more than in control slices (Figure 4C-E). 
An increase in PPF ratio concurrent with a depression of fEPSP amplitude after 
exposure to VAs has been reported [16, 17], and has been interpreted as evidence for 
presynaptic depression of calcium-dependent glutamate release. In this report we 
observed a larger depression of fEPSP amplitude in KO neurons following the exposure 
to 1.2% isoflurane. This result, coupled with data in Figure 1, further suggests that 
glutamatergic synapses are affected by the mitochondrial complex I dysfunction, 
probably due to their high energetic demand upon stimulation. This finding is consistent 
with the study by Pathak et al. that reported that electrical stimulation-induced 
depression of ATP concentration in synaptic boutons is larger in KO cells than in WT 
cells [18]. The fiber volleys – a measure of a number of action potentials arriving to 
nerve terminals – were not affected by isoflurane at either concentration tested (data not 
shown). This result indicates that the fEPSP depression could not be explained by 
attenuation of action potential conduction in KO slices. 
Depression of first and second fEPSP amplitudes after isoflurane exposure 
appears to contradict whole-cell patch-clamp data, where we did not see any changes 
to sEPSC amplitudes. This finding could be explained by increased energetic demand 
of nearly synchronous recruitment of a large number of fibers in extracellular recordings. 
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Conclusions 
We have discovered that the VA hypersensitivity of KO mice is recapitulated 
when the gene is lost in the distribution of the Vglut2 promoter. Electrophysiologic 
studies reveal that the characteristics of the CA1 of the hippocampus are not changed 
in the mutant, except when exposed to isoflurane. A low concentration of isoflurane 
decreased the frequency of sEPSCs only in the mutant. 
Since mEPSCs of KO neurons were not affected by 0.6% isoflurane, it is 
possible that isoflurane reduced the network input into CA1 pyramidal cells, rather than 
synaptic transmission within the CA1 region. Our results with sIPSCs and with field 
potentials make this explanation unlikely. Isoflurane has also been demonstrated to 
inhibit vesicle exocytosis through reduced Ca2+ influx specifically in excitatory synapses 
[19]. Ca2+ influx could be differentially affected in KO neurons in response to isoflurane, 
thereby explaining specific inhibition of sEPSC frequency following 0.6% isoflurane 
exposure. Alternatively, KO excitatory synapses, when exposed to isoflurane, may lack 
the ability to meet the increased energetic demands of spontaneous firing compared to 
the resting state of mEPSCs. It will therefore be useful to explore the 
electrophysiological effects of Ndufs4 mutation under states of high energetic demand. 
There are several energy-demanding processes of neuronal signaling, including 
reversal of Na+ entry for action potentials, reversal of Na+ entry at resting potential, 
reversal of ion fluxes through postsynaptic receptors, glutamate recycling, and reversal 
of presynaptic Ca2+ entry [20]. Since the fiber volley amplitude was not affected after 
0.6% or 1.2% isoflurane exposure in KO slices, it is unlikely that inhibition of reversal of 
Na+ entry for action potentials is the mechanism explaining hypersensitivity of KO 
animals to volatile anesthetics. Inhibition of any remaining energy-demanding processes 
could explain the hypersensitivity of KO animals.  
Mitochondria are increasingly appreciated by a broad audience as key regulators 
of neuronal activity, yet their role in the state of anesthesia is not clear. It has long been 
known that VAs specifically inhibit complex I function in isolated mitochondria from 
worms and mammals [21, 22]. Our work in worms, mice and children corroborated 
these in vitro findings implicating complex I, compared to other mitochondrial 
components, as uniquely controlling anesthetic sensitivity [6, 7, 23]. Taken together, 
these data link a very novel target of VAs to a specific facet of normal neuronal function 
and suggest that glutamatergic neurotransmission is selectively sensitive to isoflurane in 
the mutant. We hypothesize that VA inhibition of complex I in a mutant with 
compromised complex I function may deplete ATP levels such that presynaptic function 
is limited in the CA1 and perhaps elsewhere, as glutamatergic cells no longer match 
energetic demand with supply. This same pathway could exist in animals with normal 
complex I function, but require higher concentrations of isoflurane to achieve limiting 
amounts of ATP. 
Several questions remain. We cannot yet explain how our current data relate to 
the resistance of the animal to ketamine, although it is now clear that this drug has 
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many possible targets [24]. Also, we have not ruled out that mitochondria may be a de 
novo target for VAs in the mutant, although the main electrophysiologic change we 
measure in isoflurane occurs at a dose that approximates the EC50 of the drug for the 
whole animal phenotype. We infer that the simplest model is that mitochondria are in 
fact a target of VAs, and that inhibition of specific circuit elements, energy dependent 
excitatory transmission, is a mechanism that underlies sensitivity to VAs in the KO. 
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Figure Legends 
 
Figure 1. VGLUT2-specific KO mice show hypersensitivity for halothane and isoflurane 
similar to global KO mice. While GABA-specific KO and CHAT-specific KO mice show 
similar EC50s for isoflurane (ISO) and halothane (HAL) to control mice, VGLUT2-specific 
KO mice demonstrate hypersensitivity to both anesthetics. Data for the total KO mice 
was published before [7] and shown here for comparison. Anesthetic concentrations are 
expressed in % by volume. Graph bars represent mean, error bars represent standard 
deviation. EC50s for isoflurane and halothane were reduced in VGLUT2-specific KO 
mice (P < 0.001 for both isoflurane and halothane, global control: n = 10 mice for 
isoflurane, n = 6 mice for halothane, global KO: n = 10 mice for isoflurane, n = 6 mice 
for halothane, VGLUT2-specific control: n = 5 mice for isoflurane, n = 7 mice for 
halothane, VGLUT2-specific KO: n = 5 mice for isoflurane and for halothane). EC50s for 
isoflurane and halothane were not significantly different between GABA-specific KO 
mice and corresponding control mice (P = 0.176 for isoflurane, P = 0.585 for halothane. 
GABA-specific control: n = 6 mice for isoflurane, n = 5 mice for halothane, GABA-
specific KO: n = 6 mice for isoflurane and halothane). While EC50s for isoflurane were 
not significantly different between CHAT-specific KO mice and their controls (P = 0.420. 
CHAT-specific control: n = 6 mice, CHAT-specific KO: n = 5 mice), there was a small 
statistically significant difference in EC50s for halothane (P = 0.034. CHAT-specific 
control: n = 10 mice, CHAT-specific KO: n = 7 mice). See also Table S1. 
 
Figure 2. Effect of mitochondrial complex I dysfunction on excitatory and inhibitory 
synaptic function in hippocampal CA1 pyramidal neurons at baseline. (A1) 
Representative individual sEPSC event traces of control and KO neurons. (A2-A4) 
Quantification of absolute sEPSC frequency, amplitude, and decay time in control and 
KO cells (Control: n = 50 cells, KO: n = 81 cells). No statistically significant changes 
were observed in frequency (P = 0.118), amplitude (P = 0.043) or decay time (P = 
0.066) between control and KO cells. (B1) Representative individual mEPSC event 
traces of control and KO neurons. (B2-B4) Quantification of absolute mEPSC 
frequency, amplitude, and decay time in control and KO cells (Control: n = 10 cells, KO: 
n = 14 cells). No significant differences were observed in mEPSC frequency (P = 
0.364), amplitude (P = 0.930) and decay time (P = 0.334) between control and KO cells. 
(C1) Representative individual sIPSC event traces of control and KO neurons. (C2-C4) 
Quantification of absolute sIPSC frequency, amplitude, and decay time in control and 
KO cells (Control: n = 21 cells, KO: n = 18 cells). No significant differences were 
observed in sIPSC frequency (P = 0.190), amplitude (P = 0.231) and decay time (P = 
0.811) between control and KO cells. (D1) Representative individual mIPSC event 
traces of control and KO neurons. (D2-D4) Quantification of absolute mIPSC frequency, 
amplitude, and decay time in control and KO cells (n = 7 cells). No significant 
differences were observed in mIPSC frequency (P = 0.209), amplitude (P = 0.383) and 
decay time (P = 1.000) between control and KO cells. Graph bars here and in 
subsequent figures represent mean, error bars represent standard error of the mean. 
 
Figure 3. sEPSC frequency is more sensitive to isoflurane in hippocampal CA1 
pyramidal neurons of mitochondrial complex I mutant. (A) Representative sEPSC traces 
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before isoflurane exposure (Unexposed), during isoflurane exposure (Isoflurane), and 
after washout (Washout). Isoflurane concentration and genotype are shown on the left. 
(B-D) Quantification of relative sEPSC frequency, relative amplitude, and relative decay 
time (1.2% isoflurane control n = 10 cells, KO n = 14 cells, 0.6% isoflurane control n = 
13 cells, KO 14 cells). 1.2% isoflurane significantly decreased sEPSC frequency of both 
control cells (P < 0.05) and KO cells (P < 0.05). 1.2% isoflurane exposure did not affect 
sEPSC decay time (Control: P = 0.569, KO: P = 0.057) or amplitude (Control: P = 0.569, 
KO: P = 0.685) of both control and KO cells. 0.6% isoflurane exposure did not affect 
sEPSC frequency recorded from control cells (P = 0.794), but significantly decreased 
sEPSC frequency recorded from KO cells (P < 0.01). 0.6% isoflurane exposure did not 
affect sEPSC decay time (Control: P = 0.199, KO: P = 0.071) or amplitude (Control: P = 
0.146, KO: P = 0.062) of both control and KO cells. (E) Representative mEPSC traces 
before isoflurane exposure (Unexposed), during 0.6% isoflurane exposure (0.6% 
Isoflurane), and after washout (Washout). (F-H) Quantification of relative mEPSC 
frequency, relative amplitude, and relative decay time (Control: n = 10 cells, KO: n = 10 
cells). 0.6% isoflurane exposure did not affect mEPSC frequency (Control: P = 0.301, 
KO: P = 0.598), amplitude (Control: P > 0.05, KO: P = 0.670), or decay time (Control: P 
> 0.05, KO: P = 1.000) of both control and KO cells. Relative frequency, amplitude and 
decay time here and in subsequent figures were normalized to the average 
corresponding parameter prior to isoflurane exposure for each individual trace and 
expressed in %. Here and in subsequent figures u denotes unexposed, iso denotes 
isoflurane, wash denotes washout. * indicates statistically significant difference with P < 
0.05, for 0.6% isoflurane sEPSC data * indicates P < 0.01 per Bonferroni correction. 
See also Figures S1 and S2. 
 
Figure 4. Additional depression of 1st and 2nd fEPSP amplitude upon exposure to 1.2% 
isoflurane in mitochondrial complex I mutant recorded from Schaffer collateral – CA1 
synapses. (A) Representative field recording traces before isoflurane exposure 
(Unexposed), during isoflurane exposure (Isoflurane), and after washout (Washout). 
Stimulation artefacts are truncated and shown in grey. (B1-B3) Time course of 0.6% 
isoflurane on 1st normalized fEPSP, 2nd normalized fEPSP, PPF ratio. (C1-C3) Time 
course of 1.2% isoflurane exposure on 1st normalized fEPSP amplitude, 2nd normalized 
fEPSP amplitude, PPF ratio. (D-F) Quantification of 1st normalized fEPSP amplitude, 2nd 
normalized fEPSP amplitude, PPF ratio. Black horizontal bar represents isoflurane 
exposure. No difference was noted in PPF ratio between control and KO slices (P = 
0.163, n = 20 and 21 slices). 0.6% isoflurane exposure decreased 1st fEPSP amplitude 
(Control: P < 0.05, KO: P < 0.05) and 2nd fEPSP amplitude (Control: P < 0.05, KO: P < 
0.05), while increased PPF ratio (Control: P < 0.05, KO: P < 0.05) in both control and 
KO slices (Control: n = 10 slices, KO: n = 10 slices). 1.2% isoflurane exposure 
decreased 1st fEPSP amplitude (Control: P < 0.05, KO: P < 0.05) and 2nd fEPSP 
amplitude (Control: P < 0.05, KO: P < 0.05), while increased PPF ratio (Control: P < 
0.05, KO: P < 0.05) in both control and KO slices (Control: n = 11 slices, KO: n = 10 
slices). 1.2% isoflurane exposure produced larger depression of 1st fEPSP amplitude (P 
= 0.005) and 2nd fEPSP amplitude (P = 0.002) in KO slices compared to control slices. 
See also Figure S3. 
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Figure S1. Effect of mitochondrial complex I dysfunction in CHAT-specific and GABA-specific 
neurons on sEPSC parameters in hippocampal CA1 pyramidal neurons at baseline and upon 
exposure to isoflurane, related to Figure 3. (A-C) sEPSC frequency, amplitude, and decay time in 
CHAT-specific control and KO slices. No statistically significant changes were observed in frequency (P = 
0.888, Control: n = 11 cells, CHAT-specific KO: n= 17 cells), amplitude (P = 0.043) or decay time (P = 
0.851) between CHAT-specific control and KO cells. (D-F) sEPSC frequency, amplitude, and decay time 
in GABA-specific control and KO slices. No statistically significant changes were observed in frequency (P 
= 0.207, Control: n = 14 cells, GABA-specific KO: n = 24 cells), amplitude (P = 0.425) or decay time (P = 
0.042) between GABA-specific control and KO cells. (G-I) Changes in sEPSC relative frequency, relative 
amplitude, and relative decay time upon isoflurane exposure in CHAT-specific KO slices (Control: n = 7 
cells, KO: n = 13 cells). 0.6% isoflurane exposure did not affect sEPSC frequency (Control: P = 0.112, 
KO: P = 0.239), amplitude (Control: P = 0.305, KO: P = 0.368) and sEPSC decay time (Control: P = 
0.964, KO: P = 0.397) recorded from CHAT-specific control slices and KO slices. (J-L) Changes in in 
sEPSC relative frequency, relative amplitude, and relative decay time upon isoflurane exposure in GABA-
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Supplemental Data
specific KO slices (Control: n = 12 cells, KO: n = 16 cells). 0.6% isoflurane exposure did not affect sEPSC 
frequency (Control: P = 0.018, KO: P = 0.022), amplitude (Control: P = 0.046, KO: P = 0.646) or sEPSC 
decay time (Control: P = 0.472, KO: P > 0.05) recorded from GABA-specific control slices and KO slices. 
Graph bars here and in subsequent figures represent the mean, error bars represent standard error of the 
mean. 
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Figure S2. Effect of global Ndufs4 knock-out on sIPSC and mIPSC parameters in hippocampal 
CA1 pyramidal neurons upon exposure to isoflurane, related to Figure 3. (A) Representative sIPSC 
traces before isoflurane exposure (Unexposed), during isoflurane exposure (Isoflurane), and after 
washout (Washout). Isoflurane concentration and genotype group are shown on the left. (B-D) 
Quantification of relative sIPSC frequency, relative amplitude, and relative decay time (1.2% isoflurane: 
control n = 5 cells, KO n = 5 cells; 0.6% isoflurane: control n = 7 cells, KO n = 5 cells). 1.2% isoflurane 
exposure significantly increased sIPSC decay time obtained from both control cells (P < 0.05) and KO 
cells (P < 0.05). 0.6% isoflurane exposure also significantly increased sIPSC decay time obtained from 
both control cells (P < 0.05) and KO cells (P < 0.05). sIPSC amplitude of control cells decreased upon 
exposure to 0.6% isoflurane (P < 0.05). 1.2% isoflurane exposure did not affect sIPSC amplitude (Control: 
P = 0.367, KO: P = 0.367) or frequency (Control: P = 0.182, KO: P = 0.367) of both control and KO cells. 
0.6% isoflurane exposure decreased sIPSC amplitude in control cells (P < 0.05) without affecting sIPSC 
amplitude in KO cells (P = 0.093). 0.6% isoflurane exposure did not affect sIPSC frequency in both 
control and KO cells (Control: P = 0.486, KO: P = 0.093). (E) Representative mIPSC traces before 
isoflurane exposure (Unexposed), during 0.6% isoflurane exposure (0.6% isoflurane), and after washout 
(Washout). (F-H) Quantification of relative mIPSC frequency, relative amplitude, and relative decay time 
(Control: n = 7 cells, KO: n = 7 cells). 0.6% isoflurane exposure did not affect mIPSC frequency (Control: 
P = 0.964, KO: P = 0.486). 0.6% isoflurane exposure decreased the amplitude of both control and KO 
cells (Control: P < 0.05, KO: P < 0.05), and increased decay time of both control and KO cells (Control: P 
< 0.05, KO: P < 0.05) of both control and KO cells. 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Inter-pulse interval profiles of PPF ratios for global KO and control slices at baseline 
and after isoflurane exposure, related to Figure 4. (A-C) PPF ratios at various inter-pulse intervals for 
0.6% isoflurane experiment: prior to exposure, after 0.6% isoflurane exposure and after washout. (D-F) 
Inter-pulse interval profiles for 1.2% isoflurane experiment: prior to exposure, after 1.2% isoflurane 
exposure, and after washout. No significant differences between KO and control slices in PPF ratios were 
identified at either inter-pulse interval and at either treatment group (P > 0.05, n = 5 slices). 
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Supplemental Experimental Procedures 
Animals 
All animal experiments were performed in accordance with the recommendations of the Guide for the Care and Use 
of Laboratory Animals of the National Institutes of Health and were approved by the Institutional Animal Care and 
Use Committee of Seattle Children’s Research Institute.  
Mice were maintained on a standard rodent diet with 12 hours dark-light cycle at 22°C. Water and food were 
available ad libitum. Both male and female mice were used for all experiments. Mice heterozygous for Ndufs4 null 
allele (Ndufs4Δ/+) on C57BL/6 genetic background were crossed to produce wild-type (Ndufs4+/+), heterozygous 
(Ndufs4Δ/+) and knock-out (Ndufs4Δ/Δ, KO or total KO) animals. The offspring genotype was determined by 
polymerase chain reaction. KO 23-30 days-old mice were compared with the age-matched control animals. Since 
there is no reported difference in NDUFS4 protein expression levels [S1], in phenotype [S1, S2], in isoflurane or 
halothane sensitivity (data not shown) and in electrophysiological properties of CA1 pyramidal neurons between 
wild-type and heterozygous mice (data not shown), both genotypes were used for the control group. 
GABAergic-specific Ndufs4 KO (Gad2Cre/+::Ndufs4lox/lox, GABA-specific KO), VGLUT2-specific Ndufs4 KO 
(Slc17a6Cre/+::Ndufs4Δ/lox, VGLUT2-specific KO), and cholinergic-specific Ndufs4 KO (ChatCre/+::Ndufs4lox/lox, 
CHAT-specific KO) were compared to their siblings heterozygous for Ndufs4lox and heterozygous for Cre driver. 
Mouse weight information is presented in Table S1. No animals were excluded from analysis. The offspring 
genotype was determined by polymerase chain reaction. Cre expression was localized to glutamatergic neurons in 
the hypothalamus, thalamus, midbrain, hindbrain, and spinal cord for Slc17a6Cre/+ line [S3], to GABAergic neurons 
in all brain regions for Gad2Cre/+ line [S4], and to cholinergic CNS sites including nucleus basalis, medial septum, 
vertical diagonal band of broca, laterodorsal tegmental area, peduncular pontine tegmental nucleus, nucleus 
ambiguous, and cranial nerve nuclei for ChatCre/+ line [S5]. Each one of the founder lines (Ndufs4lox/lox, Ndufs4Δ/+, 
and the different Cre lines) had been backcrossed more than 10 times. The breeding strategy is Cre/+::Ndufs4Δ/+ 
crossed to an Ndufs4lox/lox or Cre/+::Ndufs4lox/lox crossed to an Ndufs4lox/lox mice, depending on the robustness of the 
Cre line and to minimize ectopic recombination. Cell-specific KO progeny did not contain any wild-type Ndufs4 
allele in any case. Animals are all genotyped using tail DNA and tested for absence of ectopic recombination at the 
end of the experiment using brain DNA. 
Slices from GABAergic-specific Ndufs4 KO (Gad2Cre/+::Ndufs4lox/lox, GABA-specific KO) and cholinergic-specific 
Ndufs4 KO (ChatCre/+::Ndufs4lox/lox, CHAT-specific KO) were compared to slices from their siblings heterozygous 
for Ndufs4lox. 
 
Anesthetic sensitivity 
Mice were anesthetized by gradually increasing isoflurane or halothane concentration while animal body 
temperature was maintained by radiant heat. Responses of the same mouse to different concentration of the same 
anesthetic were determined after 15 min of equilibration between different anesthetic concentrations. The EC50 for 
failure to respond to non-damaging tail clamp was determined by the bracketing method [S6]. Isoflurane and 
halothane were sampled from the exposure chamber and their concentrations were determined by gas 
chromatography. 
Preparation of hippocampal slices 
Mice were anesthetized with isoflurane, their brains were quickly removed and sliced (350 µm thick coronal plane) 
using the Leica VT1000S vibratome in an ice-cold oxygenated (95% O2, 5% CO2, carbogen) slicing solution (in 
mM: KCl 5, NaH2PO4 1.25, MgSO4 3.5, CaCl2 0.5, NaHCO3 26, glucose 10, sucrose 210). After incubation in 
oxygenated slicing solution for 30 min at room temperature, slices were transferred to a chamber containing 
oxygenated artificial cerebrospinal fluid (ACSF, in mM: NaCl 118, KCl 3, CaCl2 1.5, MgCl2 1, NaHCO3 25, 
NaH2PO4 1, glucose 30). Slices were allowed to equilibrate for at least 30 min in ACSF at room temperature. 
Individual slices were transferred to the recording chamber, which was superfused with oxygenated ACSF at 3.2-3.8 
ml/min flow rate. Due to difficulty in maintaining gigaohm seals for the duration of isoflurane exposure experiment 
at 37°C, all experiments on slices were performed at 30°C. Isoflurane was applied in the superfusate at equilibrated 
concentrations delivered by passing carbogen through a calibrated isoflurane vaporizer (Scivena Scientific TEC-3 
and Patterson Veterinary TEC-3). The superfusate was sampled during isoflurane exposure, and the isoflurane 
concentration was determined using gas chromatography. 
Whole-cell patch-clamp experiments 
Hippocampal pyramidal cells were visualized using differential interference contrast microscopy. Whole-cell patch-
clamp experiments were performed using borosilicate glass capillaries pulled on Sutter Instruments P-97 puller. 
Patch pipettes were filled with either a potassium gluconate-based solution (in mM: potassium gluconate 140, CaCl2 
1, MgSO4 2, EGTA 10, Na2ATP 4, NaGTP 0.4, HEPES 10) for recording spontaneous excitatory post-synaptic 
currents (sEPSCs) and miniature excitatory post-synaptic currents (mEPSCs) or a cesium chloride-based solution (in 
mM: CsCl 140, HEPES 10, phosphocreatine 10, Mg-ATP 4, Na-GTP 0.3, QX314-Br 5) for recording spontaneous 
inhibitory post-synaptic currents (sIPSCs) and miniature inhibitory post-synaptic currents (mIPSCs). Internal 
solution pH was adjusted to 7.3 using potassium hydroxide or cesium hydroxide respectively, final osmolality was 
309-314 mOsm. In addition, 10 µM α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
antagonist 6,7-Dinitroquinoxaline-2,3-dione disodium (DNQX) and 10 µM N-Methyl-D-aspartate (NMDA) 
antagonist (RS)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid ((RS)-CPP) were included in the external 
solution for recording sIPSCs. For recording mEPSCs and mIPSCs, 0.5 µM tetrodotoxin (TTX) was applied to the 
superfusate. Patch pipettes had a resistance of 3 to 5 MΩ. Recordings were performed with either an EPC10 double 
amplifier (HEKA) and digitized with a Digidata 1322A (Axon Instruments) or a MultiClamp700B Amplifier (Axon 
Instruments) and digitized with a Digidata 1400 (Axon Instruments). Patch-clamp currents were filtered at 2.1 kHz 
and sampled at 10 kHz. Holding potential was -60 mV. Series resistance was monitored during the experiments; 
recordings with substantially changed series resistance were excluded from the analysis.  
Extracellular experiments 
Extracellular recording electrodes were fabricated by pulling borosilicate glass capillaries on Sutter Instruments P-
97 puller, breaking the tip against sand paper, and filling with ACSF. Pipette resistance was less than 1 MΩ. The 
bipolar stimulating electrode was fabricated by twisting 2 Teflon-coated platinum wires (50 µm, AM-Systems). 
Stimuli were delivered by A-365 stimulus isolation unit (WPI). The stimulating electrode was positioned on 
Schaffer collateral fibers, while recording electrode was positioned in CA1 stratum radiatum for recording 
extracellular field excitatory post-synaptic potentials (fEPSPs). The amplitude of stimulation ranged from 50 to 150 
µA, and was selected to produce half-maximal fEPSP amplitude. The stimulus duration was 100 µs. Field potential 
signals were amplified using EPC10 amplifier (HEKA) and digitized with Digidata 1322A (Axon Instruments) at 
200 kHz sampling rate. Two-pulse protocol was used with 60 ms inter-pulse interval for isoflurane time course 
experiments. In some cases inter-pulse intervals in the range of 10 to 100 ms were used before isoflurane exposure, 
during isoflurane exposure and after isoflurane wash. Stimulations were applied at 0.033 Hz (every 30 s). 
Data Analysis 
Traces were analyzed with pClamp 10 software (Axon Instruments). sEPSCs, mEPSCs, sIPSCs and mIPSCs were 
analyzed for amplitude, frequency, and 90%-10% decay time. Due to high variability of baseline parameters, 
exposed and wash data were normalized to their average unexposed parameter and expressed as % of unexposed 
value. Extracellular traces were digitally filtered off-line at 10 kHz, and fEPSP amplitudes were analyzed using 
pClamp software (Axon). fEPSP amplitudes were normalized as the percent of the average of fEPSP amplitudes 
during 10 minutes of recording immediately preceding isoflurane exposure. Paired-pulse facilitation (PPF) ratios 
were calculated by dividing the amplitude of the second peak to the amplitude of the first peak. Data are expressed 
and graphed as means ± standard errors of the mean of measured responses. Cell specific EC50s are expressed as 
means ± standard deviations. Statistical analyses (two way ANOVA with post Tukey test for cell-specific in vivo 
data, Mann-Whitney U test for 2 group non-paired comparisons, Friedman test for repeated measures comparisons 
with post Tukey test) were performed in SigmaPlot 12.5. For comparison of controls and total KO values, 
significance was taken as p<0.05. When comparing changes in parameters for synaptic functions of EPSCs for 
exposure to 0.6% isoflurane, we compared six groups (3 different control groups, global KO, 2 cell specific KOs). 
Therefore, we used a Bonferroni correction for six groups leading to a level of 0.01 for significance. 
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